The State Scientific Center for Virology and Biotechnology "Vector" has begun clinical trials of the first Russian anti-smallpox chemotherapy drug NIOCH-14, the press service of Rospotrebnadzor reports.
It is noted that this drug is a joint development of the "Vector" center and the Novosibirsk Institute of Organic Chemistry. N.N.Vorozhtsova SB RAS. Currently, there is not a single domestic chemical preparation for the treatment and emergency prevention of smallpox and other orthopoxvirus diseases in humans.
The study involved 90 volunteers aged 18 to 50 years. The clinical trials will last 174 days.
Earlier it became known that the national vaccination calendar in Russia in 2020 will be replenished with a vaccine against chickenpox and rotavirus infection. Also, as noted by Veronika Skvortsova, vaccination against meningococcal infection is also carried out at the regional level, and in the future it can also be carried out at the national level.